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Abstract
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory loss and hippocampal
atrophy.

Soluble amyloid-β (Aβ)42 and plaque accumulation is implicated as the neurotoxic species in this disorder, however, at

physiological concentrations (pM-nM), Aβ42 contributes to neurogenesis, long-term potentiation, and neuromodulation. Because Aβ42

binds the α7 nicotinic acetylcholine receptors (α7nAChRs) located presynaptically on glutamatergic terminals, involved with
hippocampal dependent learning and memory, we examined the effects of the human, monomeric isoform of Aβ 42 on
glutamate release in the dentate gyrus (DG), CA3, and CA1, of isoflurane anesthetized, 6-9 month old male C57BL/6J mice.
We utilized an enzyme-based microelectrode array selective for L-glutamate measures with fast temporal (4 Hz), low spatial resolution
(50 x 100 µm) and minimal damage to the surrounding parenchyma (50-100 µm). Local application of Aβ42 (0.01, 0.1, 1.0, and 10.0
µM; ~150 nl; 1-2 seconds) elicited robust, reproducible glutamate signals in all hippocampal subfields studied. Local application of 0.1
and 1.0 µM Aβ42 significantly increased the average maximal amplitude of glutamate release compared to saline in the DG and CA1.
10.0 µM Aβ42 significantly elevated glutamate release in the DG and CA3, but not in the CA1. Glutamate release was completely
attenuated with coapplication of 10.0 µM α-Bungarotoxin, the potent α7nAChR antagonist. Coapplication of 10.0 µM tetrodotoxin,
indicates Aβ42 induced glutamate release originates from neuronal rather than glial sources. This study demonstrates that the human,
monomeric Aβ42 isoform evokes glutamate release through the α7nAChR and varies across hippocampal subfields.
Keywords: Alzheimer’s disease, amyloid beta, cognition, biosensor, neurotransmission, presynaptic, tetrodotoxin, alpha bungarotoxin,
hippocampus, nicotinic acetylcholine receptor

2

Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory loss, cognitive decline,
and hippocampal atrophy. The hallmark pathological features of AD includes amyloid-β (Aβ) plaques and neurofibrillary tangles with
evidence supporting abnormal accumulation of Aβ followed by tau-mediated neuronal injury and dysfunction [1]. This process, referred
to as the amyloid cascade hypothesis, proposes that Aβ initiates the series of pathological events leading to neuronal dysfunction, cell
death, and the eventual cognitive impairments observed in AD [2]. In AD brains, Aβ40 and Aβ42 are the predominant peptide isoforms,
the latter of which is believed to aggregate faster and thusly considered more neurotoxic [3]. For example, recent evidence supports
soluble Aβ42 dimers as the neurotoxic isoform precipitating AD pathology [4–6].
However, at physiological concentrations (pM-nM) experimental evidence suggests Aβ has a role in normal brain functions including
neurogenesis, long-term potentiation, and neurotransmitter modulation [7–9]. Aβ42 binds to the α7 nicotinic acetylcholine receptor
(α7nAChR) with picomolar affinity [10] and activation of this receptor is known to stimulate glutamate release [11]. Glutamate, the
predominant excitatory neurotransmitter in the mammalian CNS, has a strong prevalence in neocortical and hippocampal pyramidal
neurons and, therefore, plays a critical role in learning and memory [12]. Furthermore, picomolar concentrations of Aβ42 can enhance
synaptic plasticity and reference memory through activation of the α7nAChR [13]. These data suggest that endogenous Aβ42 formation
lies on a continuum whereby low concentrations of the peptide are important for normal brain function, however, when a concentration
threshold is crossed; accumulation and aggregation dominate leading to neurotoxicity [7].
The purpose of the present study was to elucidate whether Aβ42 could evoke hippocampal glutamate release through the α7nAChR.
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Because of the rapid (msec) clearance of glutamate from the extracellular space by the high-affinity excitatory amino acid transporters
[14,15] few studies have been capable of directly measuring glutamatergic neurotransmission on a subsecond timescale. To do this,
we utilized an enzyme-based microelectrode array (MEA) coupled with constant potential amperometry to independently measure
glutamate release in the dentate gyrus (DG), CA3, and CA1 of isoflurane anesthetized C57BL/6J mice. These MEAs have fast temporal
(4 Hz) [16], low spatial (50 x 100 µm) resolution and minimal damage to the surrounding parenchyma (50-100 microns) [17]. A glass
micropipette was attached to the MEA to locally apply varying concentrations of Aβ 42 (0.01 – 10.0 µM). While standard practice is to
report the concentration of solutions in the glass micropipette, it should be noted that pressure ejection of solutions from a micropipette
in vivo act as a point source with the concentration decreasing as the distance increases from the ejection site [18]. We have
determined that a tenth of the barrel concentration is diffusing to the MEA surface, which is considered further in the discussion section.
The results presented here support the ability of soluble Aβ42 to stimulate the α7nAChR leading to glutamate release that varies among
hippocampal subfields.
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Materials & Methods

Animals: Six to nine month-old, male C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, ME). Protocols for animal
use were approved by the Laboratory Animal Care and Use Committee at Southern Illinois University School of Medicine. Animals
were group housed on a 12:12 hour light: dark cycle, and food and water were available ad libitum.

Immediately following

experimentation, mice were euthanized with an overdose of isoflurane and decapitated. Brains were fixed in 4% paraformaldehyde
for histological assessment of MEA placement.

Chemicals: All chemicals were prepared and stored according to manufacturer recommendations unless otherwise noted. Human
Aβ42 was obtained from Anaspec, Inc (Fremont, CA), and stored at -80°C in 0.1 mM aliquots. Alpha-bungarotoxin (αBTx) and
tetrodotoxin (TTX) were obtained from Tocris Bioscience (Minneapolis, MN). L-glutamate oxidase (EC 1.4.3.11) was obtained from
Cosmo Bio Co. (Carlsbad, CA) and diluted in distilled, deionized water (ddH2O) to make a 1U/µl stock solution for storage at 4°C.
Sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, 1,3 phenylenediamine dihydrochloride (mPD),
sodium chloride and hydrogen peroxide (H2O2, 30% in water) were obtained from Thermo Fisher Scientific (Waltham, MA). L-glutamic
acid sodium salt, bovine serum albumin (BSA), glutaraldehyde, dopamine hydrochloride (DA) and L-ascorbic acid (AA) were obtained
from Sigma-Aldrich Co. (St. Louis, MO).
SDS-PAGE: All chemicals were obtained from Bio-Rad (Hercules, CA). Aβ42 samples were prepared similar to in vivo experiments to
determine peptide isoform. 0.1 mM Aβ42 was removed from -80°C and allowed to thaw for 30 min at 4°C. Aβ42 was serially diluted in
physiological saline (pH 7.4) to the following concentrations 10.0, 1.0, 0.1, 0.01, and 0.001 µM. A 1:4 ratio of tricine sample buffer to
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Aβ42 was prepared and loaded into the wells of a 4-20% Tris-HCl gel and run for ~90 min at 120V in 1x Tris-Tricine-SDS buffer. The
gel was fixed with 40% methanol / 10% acetic acid for 30 min, rinsed with ddH2O and stained with Coomassie G-250 Stain for 60 min
on a rotator. The Coomassie G-250 Stain was rinsed twice with ddH2O in one hour intervals on a rotator and imaged using a FluorS® MultiImager (Bio-Rad).

Enzyme-Based Microelectrode Arrays: Enzyme-based MEAs with platinum (Pt) recording surfaces (Figures 1A & B) were fabricated,
assembled, coated, and calibrated for in vivo mouse glutamate measurements as previously described [19–21]. Briefly, one of the R2
MEA Pt sites was coated with an L-glutamate oxidase, BSA, glutaraldehyde coating solution. BSA and glutaraldehyde increase the
adhesion and crosslink L-glutamate oxidase to the MEA surface. L-glutamate oxidase enzymatically degrades glutamate to αketoglutarate and the electroactive reporter molecule, H2O2. The second Pt recording site (self-referencing or sentinel site) was coated
similar to the glutamate recording site, except L-glutamate oxidase was omitted from the coating solution; therefore, unable to
enzymatically generate H2O2 from L-glutamate. A potential of +0.7 V vs a Ag/AgCl reference electrode was applied to the Pt recording
surface, resulting in a two electron oxidation of H2O2 and the current was amplified and digitized by the Fast Analytical Sensing
Technology (FAST) 16mkIII (Quanteon, LLC; Nicholasville, KY) electrochemistry instrument.

mPD Electropolymerization: A minimum of 72 hrs after enzyme coating, Pt recording surfaces were electroplated with 5 mM mPD in
0.05 M phosphate buffered saline (PBS) [22]. FAST electroplating software applied a triangular wave potential with a -0.5 V offset and
0.25 V peak-to-peak amplitude at 0.05 Hz for 20 min to create an exclusion layer that restricts the passage of AA, DA, uric acid, and
3,4-dihydroxyphenylacetic acid.
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Calibration: A minimum of 24 hrs after mPD electropolymerization, each MEA was calibrated prior to implantation to generate a
standard curve for the conversion of current to glutamate concentration [23]. The Pt recording sites and a glass Ag/AgCl reference
electrode (Bioanalytical Systems, Inc., West Lafayette, IN) were placed in a continuously stirred solution 0.05 M PBS (40.0 mL)
maintained at 37°C with a recirculating water bath (Stryker Corp., Kalamazoo, MI). Final beaker concentrations of 250 µM AA, 20, 40,
and 60 µM L-glutamate, 2 µM DA, and 8.8 µM H2O2 were used to assess MEA performance. After the H2O2 addition, a final beaker
concentration of 0.25 µM Aβ42 was added to test that Aβ42 was not inherently electrochemically active (Figure 1C). Forty MEAs (24
unique) were used with an average ± standard error of the mean (SEM) for glutamate sensitivity of 9.2 ± 0.6 pA/μM (r2 = 0.998 ± 0.001),
selectivity ratio of 1031 ± 282 to 1, and limit of detection (LOD) of 0.3 ± 0.1 μM based on a signal-to-noise ratio of 3. All MEAs were
selected based upon LOD levels lower than the expected in vivo glutamate response.

Microelectrode Array / Micropipette Assembly: A glass micropipette (1.0 mm outer diameter, 0.58 mm internal diameter; World
Precision Instruments, Inc., Sarasota, FL) was used to locally apply solutions to the mouse hippocampal subfields. Glass micropipettes
were pulled using a vertical micropipette puller (Sutter Instrument Co., Novato, CA) and the tip was “bumped” to create an internal
diameter of 12-15 µm. The tip of the micropipette was positioned between the pair of recording sites and mounted 100 µm above the
MEA surface. The micropipettes were filled with sterile filtered (0.20 µm) solutions of physiological saline (0.9% NaCl, pH 7.4), 0.01 –
10.0 µM Aβ42, 0.1 µM Aβ42 with 10.0 µM αBTx or 0.1 µM Aβ42 with 10.0 µM TTX all diluted in physiological saline. Fluid was pressureejected from the glass micropipette using a Picospritzer III (Parker-Hannafin, Cleveland, OH), with pressure (5-15 psi) adjusted to
consistently deliver volumes between 100-200 nl over 1-2 s intervals. Ejection volumes were monitored with a stereomicroscope (Luxo
Corp., Elmsford, NY) fitted with a calibrated reticule [24].
7

Reference Electrode: A Ag/AgCl reference electrode was prepared by stripping 5 mm of Teflon® off each end of a silver wire (200 μm
bare, 275 μm coated; A-M Systems, Carlsberg, WA). One end was soldered to a gold-plated test connector (Newark element14
Chicago, IL) and the other was coated with AgCl by placing the tip of the sliver wire (cathode) into a 1 M HCl plating bath saturated
with NaCl containing a stainless steel wire (anode) and applying +9 V DC using a power supply to the cathode vs the anode for 15 min.

In Vivo Anesthetized Recordings: Mice were anesthetized using 1.5-2.0% isoflurane (Abbott Lab, North Chicago, IL) in a calibrated
vaporizer (Vaporizer Sales & Service, Inc., Rockmart, GA) and prepared for in vivo electrochemical recordings as described elsewhere
[20]. The mouse was placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) fitted with a mouse anesthesia mask and
body temperature was maintained at 37°C with a water pad connected to a recirculating water bath. A craniotomy was performed to
access the hippocampus. The Ag/AgCl reference wire was remotely implanted in the right cortex. Using a microdrive (Narishige
International, East Meadow, NY) attached to the electrode holder of the stereotaxic arm, the MEA / micropipette assembly was lowered
into the DG (AP: -2.0, ML: ± 1.0, DV: -2.2 mm), CA3 (AP: -2.0, ML: ± 2.0, DV: -2.2 mm) and CA1 (AP: -2.0, ML: ± 1.0, DV: -1.7 mm),
from Bregma that was randomly assigned for each mouse [25]. Each hemisphere was randomly assigned to a different treatment
group to minimize the number of mice used. Constant voltage amperometry (4 Hz) was performed using the FAST16mkIII and FAST
software for multi-channel simultaneous recordings [26]. MEAs were allowed to reach a stable baseline for 60 min before basal
glutamate determination and pressure ejection studies.

Data Analysis: The FAST16MkIII electrochemical instrument and FAST software saves amperometric data, time and pressure ejection
events for all recording sites. Calibration data, in conjunction with a MATLAB (MathWorks, Natick, MA) graphic user interface program
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developed by Jason Burmeister Consulting, LLC (Version 6.1) was used to calculate basal glutamate and Aβ42-evoked glutamate
release. To determine extracellular glutamate concentration, the sentinel site current (pA) was subtracted from the glutamate recording
site current (pA) and divided by the slope (pA/µM) obtained during the calibration [26–29]. Basal glutamate was calculated by taking
a 10 s baseline average prior to starting Aβ42 pressure ejections in the DG, CA3, and CA1 and both hemispheres were averaged to
create a single data point per mouse. Five reproducible signals were evoked in each hippocampal subfield and averaged into a
representative signal for comparison between concentrations. Prism (GraphPad Software, Inc., La Jolla, CA) software was used for
statistical analyses. A one-way analysis of variance (ANOVA) followed by a Fisher’s LSD post-hoc test was used to compare
concentrations of Aβ42 to saline control. An unpaired, two-tailed Student’s t-test was used to compare glutamate dynamics from
coapplication of both 0.1 µM Aβ42 with 10.0 µM aBTx and 0.1 µM Aβ42 with 10.0 µM TTX to 0.1 µM Aβ42. Outliers were identified with
a single Grubbs’ test (alpha = 0.05) per group. Data are represented as mean ± SEM and statistical significance was defined as
p<0.05. Throughout the manuscript, sample size refers to the number of animals in each hippocampal subfield.

Results
We characterized the Aβ42 peptide conformation by using gel electrophoresis methods. With SDS-PAGE, the preparations analyzed
resolved to a 4.5 kDA species consistent with the monomeric isoform that was visible at the 10.0, 1.0, and 0.1 µM Aβ42 concentrations
(Figure S1). However, the lowest concentrations of Aβ42 (0.01 and 0.001 µM) resulted in undetectable levels.

Basal Glutamate
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Prior to local application studies, basal glutamate measures were assessed. Basal glutamate was similar among the DG (1.5 ± 0.3
µM; n=30), CA3 (2.0 ± 0.3 µM; n=31), and CA1 (1.9 ± 0.3 µM; n=29) hippocampal subfields as shown in Figure 2. Sample size refers
to the number of animals in each hippocampal subfield.
Local application of Aβ42
We locally applied similar volumes (Figure 3A) of 4 different Aβ42 concentrations (0.01, 0.1, 1.0, and 10.0 µM; n=9 per dose) and
physiological saline (n=8-9) as vehicle control in the DG, CA3, and CA1 hippocampal subfields. Local application of 0.1 µM Aβ42
elicited robust, reproducible glutamate signals in the mouse DG (Figure 3B), CA3, and CA1. When the maximal amplitude of Aβ42evoked glutamate release was averaged, (Figure 3C), local application of 0.1 µM (p = 0.0002), 1.0 µM (p = 0.04), and 10.0 µM (p =
0.03) Aβ42 elicited significantly more glutamate than saline control (F(4,40) = 5.170; p = 0.002) in the DG. Evoked glutamate release
from local application of 0.01 µM Aβ42 (p = 0.54) was similar to saline control in the DG. In the CA3, we observed that local application
of 1.0 µM (p = 0.04) and 10.0 µM (p = 0.001) Aβ42 elicited significantly more glutamate than saline control (F(4,39) = 3.195; p = 0.02).
Evoked glutamate release from local application of 0.01 µM (p = 0.17) and 0.1 µM (p = 0.08) Aβ42 resulted in evoked glutamate release
that was not statistically significant from saline control in the CA3. Evoked glutamate release from local application of 0.01 µM (p =
0.02), 0.1 µM (p = 0.0005), and 1.0 µM (p = 0.009) Aβ42 was significantly elevated compared to saline control (F(4,40) = 4.226; p =
0.006) in the CA1. However, evoked glutamate release from local application of 10.0 µM (p = 0.21) Aβ42 was statistically similar to
saline control in the CA1.
Coapplication of 0.1 µM Aβ42 with 10.0 µM αBTx
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To determine the contribution of glutamate release through activation of the α7nAChR, the irreversible antagonist, αBTx (10.0 µM) was
coapplied with 0.1 µM Aβ42. Previous studies have shown that 10.0 µM αBTx attenuates nicotine-induced glutamate release in the
prefrontal cortex of awake, freely behaving rats [11]. The concentration of Aβ42 peptide was chosen since it elicited the largest
glutamate release in both the DG and the CA1 and was not statistically different from the 10.0 µM Aβ42 response observed in the CA3.
When similar volumes of 0.1 µM Aβ42 with 10.0 µM αBTx and 0.1 µM Aβ42 alone (Figure 4A) was locally applied in the DG (F(4,8) =
1.598; p = 0.70), CA3 (F(4,8) = 2.259; p = 0.32), and CA1 (F(4,8) = 1.680; p = 0.40) the glutamate response was attenuated in the DG,
CA3, and CA1 (Figure 4B), resulting in a similar response to that observed with local application of saline vehicle. When these signals
were averaged (Figure 4C), coapplication of 0.1 µM Aβ42 with 10.0 µM αBTx significantly attenuated glutamate release compared to
local application of 0.1 µM Aβ42 in the DG (F(4,8) = 6.267; p = 0.02), CA3 (F(4,8) = 9.397; p = 0.04), and CA1 (F(4,8) = 13.56; p =
0.003).
Coapplication of 0.1 µM Aβ42 with 10.0 µM TTX
To determine the neuronal versus glial contribution of Aβ 42-evoked glutamate release, the reversible sodium channel blocker, TTX
(10.0 µM) was coapplied with 0.1 µM Aβ42 alone. When similar volumes of 0.1 µM Aβ42 with 10.0 µM TTX and 0.1 µM Aβ42 (Figure 4A)
was locally applied in the DG (F(9,8) = 1.020; p = 0.38), CA3 (F(9,8) = 1.895; p = 0.75), and CA1 (F(9,8) = 1.185; p = 0.51) the glutamate
response was no longer present and a decrease in basal glutamate levels was observed in the DG, CA3, and CA1 (Figure 4B). When
these signals were averaged (Figure 4C), coapplication of 0.1 µM Aβ42 with 10.0 µM αBTx significantly attenuated glutamate release
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compared to local application of 0.1 µM Aβ42 in the DG (F(9,8) = 1.808; p = 0.001), CA3 (F(9,8) = 1.615; p = 0.003), and CA1 (F(9,8)
= 1.004; p < 0.0001).

Discussion
The data presented in this manuscript indicates that local application of monomeric soluble Aβ42 evokes glutamate release through the
α7nAChR in all three hippocampal subfields studied. Magdesian and colleagues [30] have demonstrated that Aβ binds at the interface
between the acetylcholine and nicotine binding domains of the α7nAChR. Additionally, Aβ-evoked Ca2+ efflux from nerve terminals
was not increased after coapplication of nicotine suggesting similar binding sites [31,32]. Since nicotine has been shown to evoke
glutamate release via the α7nAChR [11], these studies support Aβ42 binding near the nicotinic site on α7nAChR to evoke glutamate
release.
Conflicting data exists in the literature regarding the α7nAChR-Aβ interaction with studies supporting both receptor activation and
inhibition [33]. These differences may be related to the model system employed as well as the aggregation state and concentration of
Aβ used. We selected the anesthetized mouse as our model system since this provides us with the complete hippocampal afferent /
efferent connections as well as contribution from astrocytes (glutamate uptake and/or gliotransmission). Using SDS-PAGE we have
confirmed that we are locally applying the monomeric isoform of Aβ 42. Finally the concentration of Aβ is the largest confounding
variable in the literature. Physiological concentrations of Aβ (pM to low nM) have been shown to potentiate neurotransmitter release
while supraphysiological concentrations (high nM to µM) inhibit neurotransmitter release [8]. While standard practice is to report the
concentration of solutions in the glass micropipette, it should be noted that pressure ejection of solutions from a micropipette in vivo
12

act as a point source with the concentration decreasing as the distance increases from the ejection site [18].

Using the effective

diffusion coefficient of monomeric Aβ42 (0.623*10-6 cm2s-1) as calculated by Waters [34] and the pressure ejection diffusion equation
derived from Nicholson [18] we have calculated an approximate concentration of Aβ42 surrounding the MEA. Based on an average
distance of 100 microns from the micropipette (point source) to the MEA, we have approximated the concentration of locally applied
Aβ42 surrounding the MEA to be 1.0, 10.0, 100.0 and 1000.0 nM (for micropipette concentration of 0.01, 0.1, 1.0 and 10.0 µM Aβ42,
respectively) after a 1 second pulse of ~150 nl of solution. While this is a theoretical approximation, these diffusion concentrations are
in agreement with the literature, whereby the physiological pM to low nM concentrations evoked the largest glutamate release in the
DG and CA1. Coincidentally, in the APP/PS1 mouse model of increased Aβ42 production we have noticed that the earliest increases
in glutamate release are observed in the CA1 [16] and DG (unpublished observations). These data are consistent with the concept
that physiological concentrations of Aβ modulate neurotransmitter release essential for synaptic plasticity and learning and memory
[7,13].
The most striking results from this study are the differences in Aβ 42-evoked glutamate release among the hippocampal subfields. The
largest glutamate responses were observed with 0.1 µM Aβ 42 in the DG and CA1, while 10.0 µM produced a slightly larger glutamate
response in the CA3.

These discrepancies might be attributable to the distribution of α7nAChR in the rodent hippocampus.

Autoradiographic studies indicate αBTx binding sites are slightly weaker in the CA3 compared to the DG and CA1 subfields [35]. Fewer
CA3 α7nAChRs may help to explain why the highest concentration of Aβ 42 tested evoked the largest release of glutamate in this
hippocampal subfield. Interestingly, Aβ protein deposition in humans with AD has been shown to occur first in the CA1 and DG followed
by the CA3 [36], similar to the pattern we observed with increased Aβ42-evoked glutamate release at lower concentrations in the CA1
13

and DG. Regardless, the demonstration of Aβ42-evoked glutamate release differences among the DG, CA3, and CA1 supports the
need to utilize in vivo recording techniques with high spatial resolution to be able to independently measure discrete subregions of
larger anatomical CNS structures.
While our current studies support Aβ42-evoked glutamate release is completely modulated through the α7nAChR, Aβ42 can bind the
α4β2nAChR at 100-5000 times higher concentration than α7nAChR [10]. Furthermore, Mura and colleagues [8] reported Aβ had a
dual effect on the α7 and α4β2nAChR in the rat hippocampus. The biggest difference between these two studies was that Mura and
colleagues conducted their experiments in awake, freely-behaving rats while our studies were performed in isoflurane anesthetized
mice. Isoflurane has been shown to inhibit the α4β2, but not α7nAChR [37]. Based on these data, we cannot rule out a potential role
for the α4β2 nAChR-Aβ42 modulation of glutamate release.
Gahring and colleagues [38] have demonstrated that α7nAChR are located on both neurons and astrocytes, however the role of glial
α7nAChR in glutamate release is unclear. For example, stimulation of astrocytic α7nAChR by nicotine has resulted in the release of
glutamate from mouse cortical gliosomes [39], but Salamone and colleagues reported that perfusion of Aβ 40 onto rat hippocampal
gliosomes inhibited glutamate overflow [40], which may result in decreased basal glutamate. Since the present studies support that
Aβ42 evokes glutamate release in vivo, we sought to determine the neuronal versus glial contribution by coapplying 0.1 µM Aβ42 with
10.0 µM TTX. TTX is a reversible sodium channel blocker that prevents neuronal depolarization, while gliotransmission, the result of
increased astrocytic intracellular calcium levels, would be unaffected. In the present study, coapplication of 0.1 µM Aβ 42 with 10.0 µM
TTX completely blocked Aβ42 mediated glutamate release and decreased basal glutamate levels as previously observed [27,41,42],
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supporting Aβ42-evoked glutamate release originating from predominantly neuronal activation of the α7nAChR.

Furthermore, by

blocking neuronal depolarization with TTX, the coapplied Aβ42 could still bind astrocytic α7nAChR and synergistically depress basal
glutamate. This may suggest a dual role for the α7nAChR whereby binding evokes neuronal glutamate release but blocks astrocytic
glutamate release.

While excitotoxicity has been proposed as a mechanism of neuronal death and cognitive decline associated with AD [43], the
concentration of Aβ42-evoked glutamate release observed in this study is not in the neurotoxic range for an intact CNS abundant in glia
under normal conditions [15]. Rather, the progressive accumulation of Aβ42 during disease progression could lead to persistent
activation of the α7nAChR and chronically elevate glutamate release that, over time, results in excitotoxicity. Soluble Aβ42 levels have
been shown to increase during AD progression in both humans [44,45] and mouse models of AD [34,46]. Furthermore, Aβ42 causes
protein oxidation of glutamine synthetase [47] and glutamate transporter 1 [48], the predominant isoform that accounts for ~90% of
glutamate clearance from the extracellular space. As the soluble Aβ42 concentration gradually increases, its neuromodulatory role on
glutamate release is elevated while simultaneously decreasing glutamate clearance resulting in excitotoxicity, thereby initiating the
cognitive decline associated with AD.
Furthermore, as the Aβ42 concentration increases from a physiological neuromodulatory role to the pathological hallmark observed in
AD, the α7nAChR-Aβ42 interaction may advance AD etiology through several mechanisms. First, prolonged exposure to high nM
concentrations of Aβ42 has been shown to block or desensitize α7nAChR receptor function thereby preventing the normal function of
these receptors [49]. Second, the α7nAChR-Aβ42 complex may become internalized in both neurons and astrocytes, leading to plaque

15

formation and eventual host cell lysis and plaque deposition [50]. Third, the α7nAChR-Aβ42 may serve as the initial scaffold for Aβ42
aggregation and eventual plaque accumulation [10] resulting in AD neuropathological progression [36] as previously mentioned. Taken
together, these data suggest that Aβ42 accumulation causes a functional blockade of the α7nAChR that impairs neuromodulation and
potentially cognition, which may support why drugs targeting the cholinergic and glutamatergic systems in later stages of AD are largely
unsuccessful.
In conclusion, we have demonstrated that soluble, monomeric Aβ 42 can evoke glutamate release through the α7nAChR and release
varies across hippocampal subfields. This release is mediated through a sodium channel dependent mechanism. Future studies will
determine if dimeric and trimeric isoforms of Aβ42-evoke or -inhibit glutamate release and determine the potential receptors through
which these mechanisms occur.
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Figure 1: MEA and In Vitro Calibration

A) Image of the R2 MEA used for anesthetized recordings with magnified tip (B) depicting 2 Pt
recording sites measuring 50 x 100 µm with 100 µm spacing between sites. C) A typical MEA in
vitro calibration measuring the change in current on a glutamate measuring site (green, top trace)
and a sentinel recording site (blue, bottom trace) with the addition of multiple analytes (↓), as
indicated. The addition of interferents such as AA and DA produced no current change on either
site since they are blocked by the mPD exclusion layer. Three glutamate additions showed a
stepwise increase of current on the glutamate oxidase / BSA / glutaraldehyde site, but no
response on the BSA / glutaraldehyde sentinel site. The addition of H2O2 produced a similar
increase of current on both recording sites. Finally, addition of Aβ 42 produced no change in current
on either site indicating the peptide is not electrochemically active.

Figure 2: Hippocampal Basal Glutamate

Bar graph depicting basal glutamate in the DG (n=30), CA3 (n=31), and CA1 (n=29). Sample
size refers to the number of animals in each hippocampal subfield. Basal glutamate measures
were determined by taking a 10 s baseline average prior to local application of drug or saline
control for each hippocampal subfield.
Figure 3: Local Application of Aβ42

A) Bar graph depicting a similar range of volumes was used for saline vehicle and all four
concentrations for Aβ42 in vivo. B) Representative trace of local application (↑) of Aβ 42-evoked
glutamate release (top, black trace) versus saline control (bottom, gray) trace in the DG. C)
Average glutamate response from local application of saline control and 0.01, 0.1, 1.0, 10.0 µM
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Aβ42. One-Way ANOVA with Fisher’s LSD post-hoc *p<0.05, **p<0.01, ***p<0.001 versus saline
control.
Figure 4: Coapplication of 0.1 µM Aβ42 with 10.0 µM αBTx or 10.0 µM TTX
A) Bar graph depicting a similar range of volumes was used for 0.1 µM Aβ42, 0.1 µM Aβ42 with
10.0 µM αBTx, and 0.1 µM Aβ42 with 10.0 µM TTX in all three hippocampal subfields studied. B)
Representative trace of evoked glutamate release from local application (↑) of saline (second from
bottom), 0.1 µM Aβ42 (top), 0.1 µM Aβ42 with 10.0 µM αBTx (second from top), and 0.1 µM Aβ42
with 10.0 µM TTX (bottom) in the CA1. C) Average glutamate response from local application of
0.1 µM Aβ42 with 10.0 µM αBTx was significantly attenuated versus 0.1 µM Aβ42 in the DG, CA3,
and CA1. Average glutamate response from local application of 0.1 µM Aβ42 with 10.0 µM TTX
blocked glutamate release that was significantly decreased versus 0.1 µM Aβ42 in the DG, CA3,
and CA1. Unpaired, two-tailed Student’s t-test, *p<0.05, **p<0.01, ****p<0.0001 versus 0.1 µM
Aβ42.

Supplementary Figure 1: SDS-Page Gel
SDS-PAGE showing Coomassie G-250 stained proteins consistent with Aβ42 monomer (4.5 kDA)
in the 0.1, 1.0, and 10.0 µM evaluated in vivo. Once prepared, all solutions were maintained at
room temperature for 60 minutes prior to gel loading; the same length of time the solution remains
in the glass micropipette before local application studies are started.
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